恩替卡韦治疗失代偿期乙型肝炎肝硬化的近期疗效观察

目的观察恩替卡韦治疗乙型肝炎肝硬化的疗效。方法给予35例失代偿期乙型肝炎肝硬化患者常规护肝、支持、对症和恩替卡韦治疗24周,观察患者治疗前后临床表现、生化学、病毒学指标和Child-Pugh计分改变情况。结果患者在治疗24周时,33例(94.3%)患者病情稳定,肝功能好转或恢复正常;治疗第12周和24周时分别有78.8%(26/33)和96.97%(32/33)患者HBVDNA在检测水平(500copies/ml)以下;在12周时4例患者出现HBeAg阴转,在24周时8例患者出现HBeAg阴转,1例患者出现HBeAg/HBeAb血清转换;Child-Pugh计分由治疗前11.4±0.5降至6.6±0.4(P0.05)。结论恩替卡韦治疗失代偿期乙型肝炎肝硬化患者能显著抑制病毒复制、改善肝功能,减缓病情发展,并且安全性好。     

恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效观察

目的观察恩替卡韦治疗失代偿期乙型肝炎肝硬化患者48周时的疗效。方法肝硬化患者随机分为两组,分别给予口服恩替卡韦0.5mg/d和拉米夫定100mg/d。观察24、48周时肝功能、凝血酶原活动度（PTA）、血清学、病毒学、肝纤维化指标、Child-Pugh积分等变化情况。结果 24周时肝功能、PTA、肝纤维化指标和Child-Pugh积分等均有所改善,但两组间差异无统计学意义（P〉0.05）,随着疗程的延长无明显变化。恩替卡韦组在24、48周时分别有26.1%（6/23）及30.4%（7/23）的患者出现HBeAg血清学转换,但两组间差异无统计学意义（P〉0.05）。24、48周HBV DNA水平下降值、HBV DNA阴转率恩替卡韦组高于拉米夫定组（P〈0.05）。结论恩替卡韦能有效、快速抑制失代偿期乙型肝炎肝硬化患者的病毒复制,改善肝功能。     

恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效观察

目的观察恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效。方法治疗组30例失代偿期乙型肝炎肝硬化患者,在对照组综合治疗的基础上,口服恩替卡韦片（0.5mg/d）,观察6个月时患者的临床症状、肝功能、病毒学指标的变化情况。结果治疗组在治疗6个月时,ALT从152.2±91.2U/L下降到33.2±22.1U/L,TBIL从48.9±20.5μmol/L下降到28.1±12.9μmol/L,ALB从28.47±1.22g/L升高到36.66±3.44g/L;HBVDNA阴转率为76.7%,14例Child-PughB级患者上升至A级,而对照组只有4例。结论恩替卡韦能迅速有效地改善大多数HBV引起的失代偿期肝硬化患者的生活质量。     

恩替卡韦治疗乙型肝炎失代偿期肝硬化的近期疗效观察

目的：观察恩替卡韦治疗乙型肝炎肝硬化失代偿期患者24周时的疗效。方法：乙型肝炎肝硬化失代偿期患者36例,采用恩替卡韦0.5mg/d,与32例对照组单纯支持对症治疗比较,观察24周时两组患者肝功能、Child-Pugh分级以及血清HBV DNA自基线下降的水平。结果：治疗24周时治疗组患者肝功能、Child-Pugh分级以及血清HBV DNA自基线下降的水平与对照组比较差异有显著性意义。结论：恩替卡韦能改善乙型肝炎肝硬化失代偿期患者肝功能,并能取得良好的抗病毒效果,提高生存率。     

恩替卡韦治疗失代偿期乙型肝炎肝硬化48周疗效观察

目的 观察恩替卡韦治疗失代偿期乙型肝炎肝硬化48周的疗效。方法 96例失代偿期乙型肝炎肝硬化患者被随机分为治疗组48例和对照组48例,其中治疗组给予恩替卡韦治疗48周。观察治疗前、治疗后24周和48周时的病毒学、生化学指标的变化情况。结果 患者在接受恩替卡韦治疗后24周和48周时血清HBV DNA水平小于1000 copies／ml比率分别为73．9％（34／46）和85．7％（36／42）,与对照组比较差别有显著性意义（P值分别等于0．009和0．004）;血清丙氨酸氨基转移酶复常率分别为84．8％（39146）和88．0％（37／42）,高于对照组的52．5％（21140）和44．1％（15／34）,差别有显著性意义（P值均为0．000）;Child-Pugh计分分别为8．42±2．78和8．92±2．76,较治疗前明显下降,也比对照组的10．75±3．14和11．41±2．69明显降低（P值分别为0．018和0．044）。结论 恩替卡韦治疗乙型肝炎肝硬化患者能有效地抑制病毒复制,降低HBV DNA水平,同时可以改善肝功能及Child-Pugh计分等指标。     

恩替卡韦治疗失代偿期乙型肝炎肝硬化2年疗效观察

目的观察恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效及安全性。方法 87例失代偿期乙型肝炎肝硬化患者接受恩替卡韦治疗,观察24个月时的疗效。结果 3例死亡,84例存活;生存患者肝功能指标明显改善,HBVDNA转阴率为96.4%。结论恩替卡韦能迅速有效地改善绝大多数乙型肝炎肝硬化患者的生活质量。     

恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周疗效观察

目的探讨恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化96周的临床疗效。方法应用恩替卡韦治疗HBV DNA阳性的34例慢性乙型肝炎患者和24例乙型肝炎肝硬化患者,观察96周。结果 34例慢性乙型肝炎患者治疗12周、24周、48周和96周时HBV DNA低于检测下限比率分别为61.76%（21/34）,82.35%（28/34）,94.12%（32/34）和94.12%（32/34,P〈0.05）;22例乙型肝炎肝硬化患者也分别为72.73%（16/22）,81.82%（18/22）,81.82%（18/22）和90.91%（20/22,P〈0.05）;治疗期间未发生与应用恩替卡韦相关的不良反应。结论恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化患者有明显的疗效,安全性较好。     

恩替卡韦联合阿德福韦酯对拉米夫定耐药乙肝肝硬化的疗效

目的 研究恩替卡韦（ENT）联合阿德福韦酯（ADV）治疗对拉米夫定耐药乙型肝炎肝硬化的临床疗效.方法 选取98例对拉米夫定耐药乙型肝炎肝硬化患者分为代偿期和失代偿期,两组患者均给予恩替卡韦（0.5 mg/d,qd）和阿德福韦酯（10 mg,qd）治疗.两组患者分别在治疗前、治疗24周和48周收集患者的血清样本检测HBV DNA阴转率、ALT复常率、评估Child-Pugh评分和与药物相关的不良反应.结果 治疗24周、48周时两组患者的HBV DNA阴转率、HBeAg阴转率、ALT复常率与治疗前相比均得到显著改善,治疗24周和48周时,两组HBeAg阴转率、HBV DNA阴转率、ALT复常率比较,差异有统计学意义（P＜0.05）.Child-Pugh评分与治疗前相比得到改善,但差异无统计学意义（P＞0.05）,治疗24周和48周时,两组Child-Pugh评分比较差异有统计学意义（P＜0.05）.未见不良反应和病毒学突破.结论 恩替卡韦联合阿德福韦酯治疗乙型肝炎肝硬化可以有效抑制乙肝病毒复制,延缓疾病进展,安全性良好.     

恩替卡韦治疗乙型肝炎肝硬化患者48周前后血清补体的变化

目的观察血清补体C3、C4在恩替卡韦治疗乙型肝炎肝硬化48周前后的变化,探讨恩替卡韦对乙型肝炎肝硬化患者补体的影响。方法 98例乙型肝炎肝硬化患者接受恩替卡韦治疗（10 mg口服,1次/d）48周,其中50例失代偿期肝硬化和48例代偿期肝硬化患者,以50例健康者为对照。98例乙型肝炎肝硬化患者按照HBV DNA载量分为三组：低度组（103～105IU/L）,中度组（105～107IU/L）,高度组（≥107IU/L）。根据应答情况分为：完全应答[ALT正常,HBV DNA降低至检测下限（〈1000 IU/L）和乙型肝炎e抗原（HBeAg）血清转换];部分应答（有1项或2项完全应答）;无应答（没有任何1项完全应答）。检测治疗前后补体C3、C4及ALT水平。通过配对t检验比较患者的治疗前后补体C3、C4的水平,两组间比较采用t检验,多组之间比较采用单因素方差分析。结果治疗前各组患者补体C3、C4低于正常对照组（P〈0.01）,失代偿组低于代偿组（P〈0.01）,补体C3在低度组最低（P〈0.05）、在完全应答组高于部分应答组（P〈0.01）;治疗后补体C3、C4在代偿组高于失代偿组（P〈0.01）、完全应答组高于部分应答组（P〈0.01）,补体C3在低度组最低（P〈0.05）;治疗后补体C3、C4在代偿组及完全应答组、补体C3在部分应答组、补体C4在中度组较治疗前升高（P〈0.05）。结论恩替卡韦通过抑制HBV复制,能提高代偿期肝硬化补体C3、C4水平,且治疗应答越好,补体恢复越快。     

恩替卡韦治疗失代偿期乙型肝炎肝硬化患者48周临床观察

目的观察恩替卡韦治疗乙型肝炎肝硬化患者48周疗效。方法采用随机、对照队列研究方法,将98例乙型肝炎肝硬化患者分成三组,恩替卡韦（ETV）组32例,拉米夫定（LAM）组42例,对照组24例,采用常规保肝对症治疗,疗程均为48周。观察治疗不同时间点患者的病毒学、生化学、凝血酶原时间（PT）、肝纤维化指标及Child-Pugh计分等变化情况。结果 ETV组患者HBV DNA水平显著下降,由治疗前的（6.6±1.0）log10拷贝/ml分别降低为治疗后12周、24周和48周的（3.1±1.2）、（2.8±1.1）和（2.8±1.0）log10拷贝/ml,HBV DNA转阴率优于LAM组和对照组,12周、24周、48周时依次为（59.4%、31.0%、0.0%;84.4%、66.7%、0.0%;87.5%、69.0%、0.0%）,差异均有统计学意义（P〈0.05）。在24和48周ETV组患者血清HBeAg阴转率及HBeAg/抗-HBe血清学转换率（47.6%,23.8%;52.4%,38.1%）与对照组（0.0%、0.0%;0.0%,0.0%）比较,差异有统计学意义（P〈0.05）。ALT、AST、TBil明显下降,肝纤维化指标改善,Child-Pugh计分下降,在24和48周,ETV组和LAM组较治疗前比较差异有统计学意义（P〈0.05）。结论 ETV治疗乙型肝炎肝硬化患者能有效、快速抑制病毒复制,改善肝功能、肝纤维化指标及Child-Pugh计分等。     

Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial

Aim

Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are considered among the most potent antiviral agents for the treatment of chronic hepatitis B infection. We aimed to compare treatment efficacy and safety of ETV and TDF in nucleoside‐naïve chronic hepatitis B patients.

Methods

Inclusion criteria were compensated chronic hepatitis B patients who were either hepatitis B e antigen (HBeAg)‐positive or HBeAg‐negative. Exclusion criteria were co‐infection with hepatitis C virus and/or HIV, concurrent malignancy, and decompensated cirrhosis. Virological, biochemical, and serological end‐points at week 96 and 144 were compared. Of 400 patients, 200 patients received ETV and 200 received TDF.

Results

There were no significant differences between the two groups in baseline characteristics including age (41.6 ± 11.5 vs. 41.2 ± 11.6, mean baseline hepatitis B virus DNA (5.91 ± 1.79 vs. 5.94 ± 1.68 log₁₀ IU/mL), mean baseline alanine aminotransferase (68.1 ± 64.1 vs. 76.8 ± 79.8 U/L), and cirrhosis (15.5% vs. 14.5%). At week 144 of treatment, 91 and 94% of the ETV and TDF groups, respectively, achieved undetectable hepatitis B virus DNA. In HBeAg‐positive patients, HBeAg seroconversion could be achieved in 27.4% and 33.7% at week 144 for ETV and TDF groups, respectively. Quantitative hepatitis B surface antigen dropped significantly over 144 weeks of treatment period but only 1.0 to 1.5% experienced hepatitis B surface antigen loss. Safety profiles were consistent with previous reports of monotherapy.

Conclusion

Both ETV and TDF showed potent antiviral activity against hepatitis B. Either ETV or TDF can be recommended as a treatment of choice for patients with chronic hepatitis B. Both drugs were safe and well tolerated.

     

恩替卡韦与拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者48周疗效Meta分析*

目的 评价恩替卡韦（ETV）与拉米夫定（LAM）联合阿德福韦酯（ADV）治疗乙型肝炎肝硬化失代偿期患者48 w的疗效。方法 检索MEDLINE、EMBASE、CENTRAL、Cochrane图书馆、中国期刊全文数据库、中国生物医学文献数据库、中国万方数据库、中国维普数据库建库至2015年5月的资料,纳入ETV与LAM联合ADV治疗乙型肝炎肝硬化失代偿期患者48 w的临床随机对照试验（RCT）,采用Revman5.2软件进行Meta分析。结果 共纳入9个RCT,包括联合组311例,ETV组305例。Meta分析结果显示,在治疗48 w时,联合治疗组在改善肝功能方面未见明显优于ETV治疗组,其白蛋白升高、胆红素下降、PT缩短、Child-Pugh评分下降幅度的标准化均差（SMD）分别为-0.10 （95%CI-0.31~0.12,P=0.39）、-0.00（95%CI -0.58~0.57,P=1.0）、0.19 （95%CI -0.01~0.40,P=0.07）、-0.03 （95%CI -0.24~0.18, P=0.76）;在治疗48 w时,联合治疗组病死率、血清HBV DNA转阴率、HBeAg 血清学转换率和病毒学突破率分别为5.3%、68.8%、24.1%和5.0%,与ETV治疗组的4.5%、74.8%、23.4%和2.8%比,无统计学差异（P=0.83、P=0.19、P=0.96、P=0.39）。结论 恩替卡韦与拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者具有相似的短期疗效,但其远期疗效如何尚需大样本长疗程的临床随机对照试验进一步观察。     

De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

AIM:To compare efficacy of combined lamivudine(LAM)and adefovir dipivoxil(ADV)therapy with that of entecavir(ETV)monotherapy for hepatitis B virus(HBV)-related decompensated liver cirrhosis.METHODS:A total of 120 na ve patients with HBVrelated decompensated cirrhosis participated in this study.Sixty patients were treated with combined LAM and ADV therapy(LAM+ADV group),while the other60 were treated with ETV monotherapy(ETV group)for two years.Tests for liver and kidney function,alpha-fetoprotein,HBV serum markers,HBV DNA load,prothrombin time(PT),and ultrasonography or computed tomography scan of the liver were performed every1 to 3 mo.Repeated measure ANOVA and theχ2test were performed to compare the efficacy,side effects,and the cumulative survival rates at 48 and 96 wk.RESULTS:Forty-five patients in each group were observed for 96 wk.No significant differences in HBV DNA negative rates and alanine aminotransferase(ALT)normalization rates at weeks 48(χ2=2.12 and 2.88)and96(χ2=3.21 and 3.24)between the two groups were observed.Hepatitis B e antigen seroconversion rate in the LAM+ADV group at week 96 was significantly higher in the ETV group(43.5%vs 36.4%,χ2=4.09,P<0.05).Viral breakthrough occurred in 2 cases(4.4%)by week 48 and in 3 cases(6.7%)by week 96 in the LAM+ADV group,and no viral mutation was detected.In the ETV group,viral breakthrough occurred in 1 case(2.2%)at the end of week 96.An increase in albumin(F=18.9 and 17.3),decrease in total bilirubin and in ALT(F=16.5,17.1 and 23.7,24.8),reduced PT(F=22.7 and 24.5),and improved Child-Turcotte-Pugh and the model for end-stage liver disease scores(F=18.5,17.8,and 24.2,23.8)were observed in both groups.The cumulative rates of mortality and liver transplantation were 16.7%(10/60)and 18.3%(11/60)in the LAM+ADV and ETV groups,respectively.CONCLUSION:Both LAM+ADV combination therapy and ETV monotherapy can effectively inhibit HBV replication,improve liver function,and decrease mortality.     

Antiviral therapy for hepatitis B virus‐related decompensated cirrhosis

Antiviral therapy is important in patients with hepatitis B virus (HBV)‐related decompensated cirrhosis. This therapy is beneficial in most patients for the stabilization or improvement of liver disease; however, advanced cirrhosis with a high Child–Pugh or model for end‐stage liver disease (MELD) score may have progressed and does not benefit from antiviral therapy. It is important to identify patients with severe decompensated cirrhosis who will not improve under antiviral therapy and who require liver transplantation as early as possible. Entecavir (ETV) or tenofovir disoproxil fumarate (TDF) is the first‐line therapy for nucleos(t)ide analogue (NA)‐naive patients with decompensated cirrhosis due to their potent and prompt HBV suppressive effect and low rate of drug‐resistant mutations. Patients on antiviral therapy should be monitored for virological and clinical response, compliance, drug resistance and adverse effects as well as surveillance for hepatocellular carcinoma (HCC). Additional studies of TDF and ETV are necessary to determine the optimal agent(s) for treating naive patients and those with drug‐resistant decompensated cirrhosis. In order to evaluate the effectiveness of NA for the treatment of decompensated cirrhotic patients in the real world, high quality observational studies such as registration studies of antiviral therapy for HBV‐related cirrhosis and a long‐term follow‐up in China, where a large number of such patients are found, are recommended.     

乙型肝炎肝硬化失代偿期与酒精性肝硬化失代偿期患者血小板参数变化的临床分析

目的探讨不同HBV DNA水平乙型肝炎肝硬化失代偿期与酒精性肝硬化失代偿期血小板计数（PLT）及血小板平均体积（MPV）变化的临床意义。方法对36例健康人、38例HBV DNA〈105拷贝/ml乙型肝炎肝硬化失代偿期患者、36例HBV DNA〉105拷贝/ml乙型肝炎肝硬化失代偿期患者及31例酒精性肝硬化失代偿期患者的外周血PLT及MPV进行测定及分析。结果与健康人相比,乙型肝炎肝硬化及酒精性肝硬化患者PLT均下降,差异有统计学意义（P〈0.05）;与酒精性肝硬化失代偿期患者相比,HBV DNA〉105拷贝/ml乙型肝炎肝硬化失代偿期患者PLT下降,差异有统计学意义（P〈0.05）;不同HBV DNA水平的乙型肝炎肝硬化失代偿期患者PLT均下降,差异有统计学意义（P〈0.05）。与健康人相比,酒精性肝硬化失代偿期、HBV DNA〉105拷贝/ml乙型肝炎肝硬化失代偿期患者MPV均下降,差异有统计学意义（P〈0.05）;与酒精性肝硬化失代偿期患者相比,HBV DNA〉105拷贝/ml乙型肝炎肝硬化失偿代期患者MPV下降,差异有统计学意义（P〈0.05）;不同HBV DNA水平的乙型肝炎肝硬化失代偿期患者MPV变化,差异有统计学意义（P〈0.05）。结论乙型肝炎肝硬化失代偿期患者高载量HBV DNA对血小板参数降低有一定的影响。     

Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis

AIM: To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients. METHODS: One hundred and forty patients with HBVrelated decompensated cirrhosis were recruited, 70 patients were treated with combined LAM and ADV de novo therapy, and the other 70 patients were treated with LAM alone as controls. The follow-up period was 144 wk. All patients with LAM resistance were shifted to ADV. RESULTS: The percentage of HBV-related decompensated cirrhosis patients with undetectable HBV DNA inde novo combination group was 51.6% (33/64), 84.2% (48/57), and 92.3% (49/53) by weeks 48, 96, and 144, respectively. In monotherapy group, HBV DNA negativity rate was 46.1% (30/65), 56.1% (32/57), and 39.2% (20/51) by weeks 48, 96 and 144, respectively. There was a significant difference between the two groups by weeks 96 and 144 (P = 0.012 and 0.001). The hepatitis B e antigen seroconversion rate was 28.1% (9/32), 40.0% (12/30), and 53.6% (15/28) in the combination group by weeks 48, 96 and 144, respectively, and 24.2% (8/33), 31.0% (9/29), and 37.0% (10/27) by weeks 48, 96 and 144, respectively, in monotherapy group. A total of 68.6% (44/64), 84.2% (48/57), and 92.5% (49/53) patients achieved alanine aminotransferase (ALT) normalization by weeks 48, 96 and 144, respectively in the combination group. In monotherpy group, the ALT normalization rate was 64.6% (42/65) by week 48, 73.7% (42/57) by week 96, and 80.4% (41/51) by week 144. No patients in the combination group exhibited detectable resistance for at least 144 wk. The cumulative resistance rate in monotherapy group at weeks 48, 96, and 144 was 20.0%, 36.8%, and 56.9%. Both combination group and monotherapy group demonstrated an improvement in Child-Turcotte Pugh and Model for End-Stage Liver Disease scores at weeks 48, 96, and 144. All patients tolerated both combination and monotherapy. The ceratinine levels and glomerular filtration rate remained norma     

恩替卡韦联合安络化纤丸治疗乙型肝炎肝硬化32例疗效分析

目的 观察恩替卡韦(ETV)联合安络化纤丸治疗乙型肝炎肝硬化的疗效.方法　将61例乙型肝炎肝硬化患者随机分为2组,治疗组32例,对照组29例.治疗组采用ETV 0.5 mg/d,联合安络化纤丸6 g/d,2次/d,治疗12个月;对照组采用ETV 0.5 mg/d,治疗12个月.结果　治疗12个月时治疗组与对照组患者的血...     

替诺福韦酯和恩替卡韦对慢性乙型肝炎初治患者疗效的荟萃分析

目的评价替诺福韦酯(TDF)和恩替卡韦(ETV)对慢性乙型肝炎(CHB)初治患者抗病毒的疗效及安全性。方法对2006年1月至2016年10月在国际生物医学期刊有关TDF和ETV治疗CHB的临床研究进行质量评价,并对相关文献进行荟萃分析。结果共纳入6篇文献。荟萃分析结果显示ETV和TDF抗病毒治疗的HBV DNA转阴率差异无统计学意义[48周时的RR=1.19,95%CI=1.09~1.30;96周时的RR=1.08,95%CI=1.02~1.14];两种药物的ALT复常率及HBeAg血清学转换率同样差异无统计学意义;且两种药物长期使用安全性良好,未观察到严重不良反应。结论 ETV和TDF对CHB核苷(酸)类药物初治患者抗病毒疗效相似,但仍需进一步观察远期治疗的安全性。     

Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir

This study evaluated the clinical implications of hepatitis B surface antigen quantification (qHBs Ag) in chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) and identified the association between qHBs Ag and the risk of hepatocellular carcinoma (HCC) in these patients.Between January 2007 and December 2018, the qHBs Ag and clinical data of 183 CHB patients who initially received ETV (n = 45, 24.6%) or TDF (n = 138, 75.4%) were analyzed.The mean follow-up period of the 183 CHB patients was 45.3 months, of which 59 (32.2%) patients showed a reduction in qHBs Ag by >50% after 1 year of antiviral treatment (ETV or TDF). The HCC development (P = .179) or qHBs Ag reduction (P = .524) were similar in the ETV and TDF groups. Patients with a ≥50% decrease in qHBs Ag had a significantly lower incidence of HCC or decompensated cirrhosis complications (P = .005). Multivariate analysis showed that a >50% reduction of qHBs Ag (hazard ratio 0.085, P = .018) and the presence of cirrhosis (hazard ratio 3.32, P = .016) were independent factors predicting the development of HCC.Patients whose qHBs Ag value decreased >50% at 1 year after antiviral treatment for CHB showed a significant decrease in HCC or decompensated cirrhosis events. A reduction in qHBs Ag could be used as a predictive factor of HCC development or critical complications in CHB patients treated with TDF or ETV.